Alector (NASDAQ:ALEC) Insider Grace Wong-Sarad Sells 5,165 Shares of Stock

Alector, Inc. (NASDAQ:ALEC) insider Grace Wong-Sarad sold 5,165 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.67, for a total transaction of $13,790.55. Following the completion of the sale, the insider owned 109,640 shares of the company’s stock, valued at approximately $292,738.80. This represents a 4.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Grace Wong-Sarad also recently made the following trade(s):

• On Friday, September 4th, Grace Wong-Sarad sold 3,625 shares of Alector stock. The stock was sold at an average price of $2.51, for a total transaction of $9,098.75.
• On Wednesday, September 2nd, Grace Wong-Sarad sold 656 shares of Alector stock. The stock was sold at an average price of $2.75, for a total value of $1,804.00.

Alector Price Performance

Shares of NASDAQ:ALEC opened at $2.46 on Friday. The company’s 50-day moving average is $1.91 and its 200 day moving average is $2.06. Alector, Inc. has a fifty-two week low of $1.09 and a fifty-two week high of $3.40. The company has a market capitalization of $274.68 million, a P/E ratio of -2.24 and a beta of 0.65. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.26 and a current ratio of 5.26.

Alector (NASDAQ:ALEC) last posted its earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%. The firm had revenue of $3.32 million during the quarter, compared to the consensus estimate of $1.71 million. On average, equities research analysts forecast that Alector, Inc. will post -0.87 earnings per share for the current year.

Institutional Trading of Alector

Several hedge funds have recently bought and sold shares of ALEC. Bank of America Corp DE grew its holdings in shares of Alector by 1.8% in the second quarter. Bank of America Corp DE now owns 343,909 shares of the company’s stock valued at $481,000 after purchasing an additional 5,927 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Alector by 3.4% during the third quarter. Mackenzie Financial Corp now owns 283,712 shares of the company’s stock valued at $840,000 after buying an additional 9,270 shares during the last quarter. Hershey Trust Co. raised its holdings in shares of Alector by 100.0% in the fourth quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock worth $32,000 after buying an additional 10,286 shares during the period. Jane Street Group LLC lifted its stake in shares of Alector by 4.7% during the 1st quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock worth $316,000 after acquiring an additional 11,618 shares during the last quarter. Finally, Diversified Trust Co increased its stake in Alector by 83.6% in the first quarter. Diversified Trust Co now owns 25,895 shares of the company’s stock worth $56,000 after purchasing an additional 11,793 shares during the period. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Analyst Ratings Changes

ALEC has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Alector from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings upgraded Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.62.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.